ArticleJournal of clinical medicine2022
Analysis of the Impact of the Presence of Phylum Cyanobacteria in the Microbiome of Patients with Breast Cancer on Their Prognosis.
Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.
- Guideline for designing microbiome studies in neoplastic diseases.GeroScience · 2024Guideline
- Association between breast cancer risk factors and blood microbiome in patients with breast cancer.Scientific reports · 2025Article
- Blood Microbiota and Its Products: Mechanisms of Interference with Host Cells and Clinical Outcomes.Hematology reports · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Cyanobacterial blooms caused by Cyanobacteria adversely affect the health of the people living in their vicinity. We elucidated the effect of Cyanobacteria in patients with breast cancer. The serum microbiome of the patients with breast cancer was analyzed using NGS. Serologic tests were performed to analyze the association between the factors affecting the liver function of patients with breast cancer and the amount of Cyanobacteria. In addition, the recurrent-free survival of patients with breast cancer according to the abundance of Cyanobacteria was analyzed. The abundance of Cyanobacteria tended to be correlated with the serological results related to liver function. A high abundance of Cyanobacteria seemed to be more related to late-stage breast cancer. A high recurrent-free survival was related to a low abundance of Cyanobacteria. Even though no toxicity study was conducted, this study demonstrates the impact of phylum Cyanobacteria on the prognosis of patients with breast cancer. Thus, the abundance of Cyanobacteria in the microbiome can help predict the prognosis of patients with breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.